

## **NOVEL RT-qPCR ASSAYS ENABLE RAPID DETECTION AND DIFFERENTIATION BETWEEN SARS-COV-2 OMICRON (BA.1) AND BA.2 VARIANTS**

Oran Erster<sup>1§</sup>, Areej Kabat<sup>1</sup>, Hadar Asraf<sup>1</sup>, Virginia Levy<sup>1</sup>, Batya Mannasse<sup>1</sup>, Roberto Azar<sup>1</sup>, Itai Nemet, Limor Kliker, Shay Fleishon<sup>1</sup>, Michal Mandelboim,<sup>1,3</sup>, Ella Mendelson<sup>1,3</sup>, Neta S Zuckerman<sup>1</sup>

<sup>1</sup>Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Ramat Gan, Israel.

<sup>2</sup>Israel Institute for Biological Research

<sup>3</sup>School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

<sup>§</sup>Corresponding author contact information: [oran.erster@sheba.health.gov.il](mailto:oran.erster@sheba.health.gov.il)

### **ABSTRACT**

In this report, we describe the development and initial validation of novel SARS-COV-2 Omicron-specific reactions that enable the identification of Omicron (BA.1) and BA.2 variants. Mutations that are either shared by both BA.1 and BA.2, or are exclusive for BA.1 or for BA.2 were identified by bioinformatic analysis, and corresponding probe-based quantitative PCR reactions were developed to identify them. We show that multiplex combinations of these reactions provide a single-reaction identification of the sample as BA.1, BA.2, or as non-Omicron SARS-COV-2. All four reactions described herein have a sensitivity of less than ten copies per reaction, and are amendable for multiplexing. The results of this study suggest that the new assays may be useful for testing both clinical and environmental samples to differentiate between these two variants.

**Keywords:** SARS-COV2, Omicron, variants, BA.1, BA.2, Molecular Diagnostics, qPCR, differentiation

## INTRODUCTION

The emergence of the SARS-COV-2 Omicron variant, formerly designated B.1.529, and currently designated BA.1, resulted in resurgence of morbidity and increased mortality worldwide, including countries with high vaccination rates, where the SARS-COV-2 Delta variant circulation already decreased (Elliott et al. 2022). Several weeks after the global spreading of the BA.1 variant, a subsequent spreading of a related variant, BA.2, was observed in several countries (Desingu and Nagarajan, 2022). The global circulation of BA.2 increases gradually, in parallel with the on-going circulation of BA.1. The epidemiological and medical consequences of the co-circulation these two variants are not well understood, as well as the differences between them, with respect to infectivity, pathogenicity and vaccine evasion (Pulliam et al. 2021, Yu et al. 2022). The rapid pace in which SARS-COV-2 (SC-2) variants emerge and spread globally, poses a substantial challenge for efficient surveillance, rendering cell culturing and whole genome sequencing often insufficient for providing fast and reliable data. We previously demonstrated that rapid, affordable and high throughput differentiation between co-circulating SC-2 variants can be accomplished using multiplex quantitative PCR (qPCR), and that this approach can complement and, in some cases, outperform genomic sequencing and similar approaches, for SC-2 variant identification (Erster et al. 2021a, Erster et al. 2021b). More recently, we reported on the development of qPCR-based assays that specifically identify BA.1 samples and allow straightforward scaling-up for high throughput testing (Erster et al. 2022). In this report, we describe, to our knowledge for the first time, differential RT-qPCR assays that rapidly distinguish between BA.1 and BA.2.

## 2. MATERIALS AND METHODS

### *2.1 Clinical samples*

Clinical samples were prepared as described previously (Erster et al. 2021a). Briefly, nasopharyngeal swabs were collected from patients for diagnostic purpose. RNA was extracted and used for clinical testing. Samples were processed and RNA was extracted as described previously ([doi.org/10.1101/2021.10.11.21264831](https://doi.org/10.1101/2021.10.11.21264831)).

## 2.2. Cell culture

Nasopharyngeal swab samples were used to infect Vero-6 cells as described previously ([doi.org/10.1101/2021.10.11.21264831](https://doi.org/10.1101/2021.10.11.21264831)). Upon the onset of cytopathic effect (CPE), the medium was collected and cultured virus was examined by RNA extraction and subsequent PCR.

## 2.3. Design of BA.1 and BA.2-specific reactions

Identification of BA.1 and BA.2 specific mutations was performed by aligning complete genomes of BA.1, BA.2, A19 (Wuhan SC-2) and Delta. Genome sequences were obtained from the GISAID initiative website (<https://www.gisaid.org/>). Sequences were aligned and analyzed using the Geneious software package (<https://www.geneious.com/>). Selected regions were examined again using the global analysis of the NextStrain website tools (<https://nextstrain.org/sars-cov-2/>), where each mutation was tested separately, to ensure its uniqueness. Primers and probes were designed and tested using the Primer 3 program (<https://bioinfo.ut.ee/primer3-0.4.0/>) embedded in the Geneious software.

## 2.4. RT-qPCR assays

Assembly of quantitative RT-PCR (RT-qPCR) was as described before ([doi.org/10.1101/2021.10.11.21264831](https://doi.org/10.1101/2021.10.11.21264831) and [doi.org/10.1101/2021.12.07.21267293](https://doi.org/10.1101/2021.12.07.21267293)). Briefly, SensiFast master mix (<https://www.meridianbioscience.com/lifescience/>) was used with the specific primers and probes combination for each reaction. For environmental samples. The primers and probes sequences and additional data are detailed in **Table 1**. The reaction components are detailed in **Table 2**. The cycling conditions for the Omicron reactions were as follows: 16 min. at 45°C, 2'20" at 95°C, 45X [4sec at 95°C, 10sec at 55°C, 10sec at 60°C]. Fluorescence was read during the extension step in each cycle.

## 2.5 Design and synthesis of *In vitro* transcribed control standards

In order to perform absolute quantification of target copies using the novel reactions, and to evaluate their analytical sensitivity, RNA targets for each reaction were synthesized, as described previously ([doi.org/10.1101/2021.05.19.21257439](https://doi.org/10.1101/2021.05.19.21257439)). Briefly, a region spanning the qPCR target sequence was amplified and transcribed to RNA using an *In vitro* transcription kit (<https://www.thermofisher.com/>). The resulting *In vitro* transcribed (IVT) RNA was purified, quantified and diluted. Calibration curves

were generated for each reaction using the synthesized standards, and the analytical limit of detection was determined.

**Table 1. Primers and probes used in this study.** Bold, underlined letters represent deliberate mismatch nucleotides that were inserted to increase specificity and minimize secondary structure formation.

Primer name	Sequence 5'->3'	Reference
SC-2 inclusive detection (E-sarbeco reaction)		
E_Sarbeco_F1b	GTTAATAGCGTACTTCTTTTCTTGC	Corman <i>et al.</i> <sup>a</sup>
E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	Corman <i>et al.</i>
E_Sarbeco_P1	ACACTAGCCATCCTTACTGCGCTTCG	Corman <i>et al.</i>
BA.1 + BA.2 detection (N <sub>del</sub> detection)		
28322 Fwd	TTTGGTGGACCCTCAGATTC	Erster <i>et al.</i> <sup>b</sup>
28424 Rev	CGCAGTATTATTGGGTAAACCTTG	Erster <i>et al.</i> <sup>b</sup>
28354 probe	FAM-CCAGAATGGTGC <del>GG</del> CGGATC-BHQ1	Erster <i>et al.</i> <sup>b</sup>
BA.1 specific detection (S <sub>211del</sub> reaction)		
22174 Fwd	GTTATTTTAAAATATATTCTAAGCACACG	Erster <i>et al.</i> <sup>b</sup>
22248 Rev	TAAAGCCGAAAAACCCTGAG	Erster <i>et al.</i> <sup>b</sup>
22206 probe	ATTATAGTGC <del>GT</del> GAGCCAGAAGATCTCC	Erster <i>et al.</i> <sup>b</sup>
BA.2 specific detection 1 (S <sub>24del</sub> reaction)		
21611Fwd	CTCTAGTCAGTGTGTTAATCTTAT	This study
21699 Rev	GTCAGGCTAATAAACACCACGTG	This study
21637 probe	FAM-CCAGAACTCAATCATACTAATTCTTTC-BHQ1	This study
BA.2 specific detection 2 (Orf6 <sub>D61L</sub> reaction)		
27345 Fwd	ATATTCTCAATTAGATGAAGAGC	This study
27370 Probe	FAM-CCAATGGAGATTCTC <del>G</del> AAACGAACATG-BHQ1	This study
27422 Rev	TCAGTGCCAAGAAAAGAATAAT	This study
Endogenous control (Human RNase P)		
Rnase P-Fwd	AGATTTGGACCTGCGAGCG	CDC <sup>c</sup>
Rnase P-Rev	GAGCGGCTGTCTCCACAAGT	CDC <sup>c</sup>
Rnase P-P	Cy5-TTCTGACCTGAAGGCTCTGCGG –BHQ2	CDC <sup>c</sup>

<sup>a</sup> The F1b primer was modified for better compatibility with multiplexing.

<sup>b</sup>Reference: [doi.org/10.1101/2021.12.07.21267293](https://doi.org/10.1101/2021.12.07.21267293)

<sup>c</sup><https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>.

**Table 2. Compositions of the multiplex assays used in this study.** The volume ( $\mu$ l) of each component and the stock and final concentrations of the primers and probes are indicated. For each probe, the fluorophore used is indicated. Conc. / Rxn: concentration per reaction.  $\mu$ l/ Rxn:  $\mu$ l per reaction.

<b>E-sarbeco + N<sub>31del</sub> + S<sub>24del</sub>+ RNaseP</b>			<b>E-sarbeco + Orf6<sub>D61L</sub></b>		
	Conc. / Rxn	$\mu$ l/ Rxn		Conc. / Rxn	$\mu$ l/ Rxn
SensiFast Probe One-Step		10	SensiFast Probe One-step		10
H <sub>2</sub> O		1.55	H <sub>2</sub> O		3.1
E-Sarbeco-F1b 40 $\mu$ M	500nM	0.25	E-Sarbeco-F1b 40 $\mu$ M	400nM	0.2
E-Sarbeco-R 40 $\mu$ M	500nM	0.25	E-Sarbeco-R 40 $\mu$ M	400nM	0.2
E-Sarbeco-P TexasRed 20 $\mu$ M	250nM	0.25	E-Sarbeco-P TXred 20 $\mu$ M	200nM	0.2
COV19_28322Fwd_F 40uM	600nM	0.3	CoV19 21611Fwd 40uM	600nM	0.3
COV19_28412 Rev 40uM	600nM	0.3	Cov19 21699 Rev 40uM	600nM	0.3
COV19_28354_P 20uM HEX	300nM	0.3	21637 Probe FAM 20uM	300nM	0.3
CoV19 21611Fwd 40uM	600nM	0.3	RNase inhibitor		0.2
Cov19 21699 Rev 40uM	600nM	0.3	RT-Enzyme SensiFast		0.2
21637 Probe FAM 20uM	300nM	0.3	RNA		5
RNasP-F	300nM	0.15	<b>Total</b>		<b>20</b>
RNasP-R	300nM	0.15			
RNasP-P / Cy-5	200nM	0.15			
RT-Enzyme SensiFast		0.25	<b>E-sarbeco + S<sub>211del</sub></b>		
RNase inhibitor		0.2	SensiFast Probe One-step		10
RNA		5	H <sub>2</sub> O		3.1
<b>Total</b>		<b>20</b>	E-Sarbeco-F1b 40 $\mu$ M	400nM	0.2
			E-Sarbeco-R 40 $\mu$ M	400nM	0.2
			E-Sarbeco-P TXred 20 $\mu$ M	200nM	0.2
			COV19_22174Fwd_F 40uM	600nM	0.3
			COV19_22248 Rev 40uM	600nM	0.3
			COV19_22206_P 20uM FAM	300nM	0.3
			RNase inhibitor		0.2
			RT-Enzyme SensiFast		0.2
			RNA		5
			<b>Total</b>		<b>20</b>

## ETHICAL STATEMENT

This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Sheba Medical Center institutional review board (7045-20-SMC). Patient consent was waived as the study used remains of clinical samples and the analysis used anonymous clinical data.

### 3. RESULTS

#### 3.1. Design of BA.1/BA.2 inclusive and selective PCR tests

In order to allow both inclusive and selective identification of BA.1 and BA.2, complete genome sequences of A19 (Wuhan strain), Delta (B.1.617.2), BA.1 and BA.2 were analyzed, to identify sequences that are unique and common for both BA.1 and BA.2, and sequences that are exclusively unique to either one of them, and are absent from A19 and Delta genomes. Four such regions were identified and selected. The deletion in the Nucleocapsid (N) gene, at amino acid position 31 ( $N_{31del}$ ) is common to both BA.1 and BA.2 (**Figure 1A**). In this reaction, the probe is complement to the deletion site and cannot bind to the WT sequence (**Figure 2A**). The deletion at position 211 and insertion at positions 214-216 of the spike (S) gene are exclusive for variant BA.1 (**Figure 1B, Figure 2B**). The deletion at position 24 of the spike gene and the codon substitution at position 61 of the Orf6 gene, are both unique for BA.2 (Orf6<sub>D61L</sub> and  $S_{24del}$ , **Figure 1C,D** and **Figure 2C,D**, respectively). Based on these mutations, four probe-based qPCR reactions were designed, where the probe in each reaction is complementary to the mutated sequence, as depicted in **Figure 2**.

#### 3.2. Evaluation of the analytical sensitivity of the new reactions

The  $S_{24del}$  reaction was combined in a multiplex that contained also the E-sarbeco inclusive reaction and the endogenous control human RNase P reaction. A pool of IVT targets corresponding to the multiplex reaction tested, was serially diluted and used with the new multiplex. Three multiplex reactions were tested: E-sarbeco +  $N_{31del}$  +  $S_{24del}$  + hRNase P, E-sarbeco +  $S_{211del}$ , and E-sarbeco + Orf6<sub>D61L</sub>. Based on the calibration curve analyses, the analytic limit of detection for the E-sarbeco, hRNaseP,  $N_{31del}$ , and  $S_{24del}$  was determined to be between 1 and 10 copies per reaction (**Figure 3A-D**).

#### 3.3. Identification of BA.1 and BA.2 clinical samples

Clinical samples previously identified as Delta (B.1.617.2), BA.1 and BA.2 by sequencing were tested in different combinations of the inclusive and selective reactions. Out of 36 samples examined, four were identified as Non-BA.1/BA.2 (all were previously identified as Delta), 10 were identified as BA.1 (previously identified as Omicron) and 21 were identified as BA.2 (**Table 3**). One sample (51039) was positive only in the  $N_{31del}$  reaction with a Cq value of 38.99 and was therefore classified as "Unclassified sample". The Cq values of the samples ranged between nine (Cultured sample) and 41

(Weak clinical sample), demonstrating that the sensitivity of the reactions with clinical samples was consistent with the results of the analytical sensitivity calibration.

**Table 3. Examination of clinical samples using the BA.1 and BA.2 reactions.** Each sample was tested using combinations of the inclusive E-sarbeco reaction and the novel BA.1/BA.2 reactions. Nan: No amplification. N.T.: Not tested. The classification of each sample based on the results is indicated.

	All COV19	BA.1+2	BA.1 ONLY	BA.2 ONLY	BA.2 ONLY	Internal control	
Sample	Cov19 E	N-31del	S-211DEL	Orf6-D61L	S-24del	RNAse P	Classification
1796	26.75	28.12	NaN	29.76	29.31	32.00	BA.2
21499	31.00	33.73	NaN	26.02	30.10	24.00	BA.2
23164	24.97	NaN	NaN	NaN	NaN	28.37	Non-Omicron
23166	23.70	NaN	NaN	NaN	NaN	24.93	Non-Omicron
23172	18.84	NaN	NaN	NaN	NaN	31.76	Non-Omicron
23173	24.88	NaN	NaN	NaN	NaN	25.23	Non-Omicron
50804	16.70	15.48	17.39	NaN	NaN	24.74	BA.1
50858	15.10	13.75	13.63	NaN	NaN	29.37	BA.1
50859	15.22	13.46	13.17	NaN	NaN	25.12	BA.1
50860	12.08	12.46	9.03	NaN	NaN	NaN	BA.1
50862	12.40	9.73	10.56	NaN	NaN	NaN	BA.1
50864	13.17	9.00	11.56	NaN	NaN	NaN	BA.1
50866	12.83	10.62	10.38	NaN	NaN	NaN	BA.1
50867	11.50	9.26	13.07	NaN	NaN	26.01	BA.1
51030	25.65	28.82	24.98	NaN	NaN	29.28	BA.1
51038	33.50	34.33	40	NaN	NaN	26.63	BA.1
51039	NaN	38.99	NaN	NaN	NaN	30.00	Unclassified
51040	29.98	31.70	NaN	30.89	30.18	27.19	BA.2
51041	21.87	24.60	NaN	26.11	20.82	28.90	BA.2
51042	31.02	32.64	NaN	27.81	29.93	30.60	BA.2
51044	32.47	32.85	NaN	34.09	33.82	29.26	BA.2
51045	34.36	35.96	NaN	36.65	35.06	28.44	BA.2
51046	23.43	25.64	NaN	29.91	24.53	27.00	BA.2
51048	25.57	28.08	NaN	29.11	26.03	31.00	BA.2
51057	39.11	40.17	NaN	40.76	40.50	29.72	BA.2
51060	24.77	25.92	NaN	27.32	26.05	29.23	BA.2
51062	25.96	26.83	NaN	31.06	29.79	26.98	BA.2
51066	19.05	21.68	NaN	18.76	18.76	38.00	BA.2
51068	29.46	30.53	NaN	31.66	32.19	27.84	BA.2
51070	24.92	26.17	NaN	29.11	26.97	29.03	BA.2
51081	23.64	25.08	NaN	27.40	23.03	30.62	BA.2
51085	27.91	29.05	NaN	30.78	30.33	32.03	BA.2
51094	20.13	20.83	NaN	23.56	23.08	27.93	BA.2
51097	33.01	33.68	NaN	37.71	34.84	26.09	BA.2
51100	37.25	34.98	NaN	N.T.	36.25	28.48	BA.2
51105	36.91	35.73	NaN	N.T.	26.26	30.71	BA.2

## DISCUSSION


The constant need to rapidly identify new and emerging SC-2 variants for clinical, epidemiological and research purposes necessitates vigilant and continuous development of new tools. Since the onset of the SC-2 pandemic, the increased infectivity of the SC-2 variants compared with the initial strain, led to their unprecedented spread in the entire globe, within a matter of a few months (Volz *et al.* 2021, Chakraborty *et al.* 2021, Lambrou *et al.* 2022). Due to their increased infectivity and pathogenicity, the effect of the spreading of different SC-2 variants on public health can be significant and so is the demand for adequate diagnostic tools. While whole-genome sequencing is ultimately the best classification tool, its implementation as a rapid, high-throughput, and available diagnostic tool worldwide, is not yet applicable. Commercial products, such as the Seegene Novaplex and Osang GeneFinder SARS-COV-2 variant kits (<https://seegenetech.com>, [www.osanghc.com](http://www.osanghc.com)) can identify specific mutations, which are associated with major SC-2 variants. However, these kits often target mutations that are not exclusive to a particular variant, such as the spike N501Y or 69-70 deletion, or mutations that can occur, although in a low frequency, independently of the variant type, such as the spike L452R. Furthermore, some of these kits require subsequent testing of the same sample more than once, and the assumed variant identity is determined based on a combination of several separate tests ([www.thermofisher.com/](http://www.thermofisher.com/)). The reactions described herein are specific and can distinguish between BA.1/BA.2 and non-BA.1/BA.2, in a single assay. The ability to distinguish between closely related, but not identical variants may have both clinical and research consequences, and its affordability may render it applicable for immediate use in many diagnostic laboratories, where genomic (or Sanger-based) sequencing is not available. Lastly, positive identification of BA.1 and/or BA.2 RNA is advantageous when testing environmental samples, which usually represent a heterogeneous pool of many individual sources. Negative identification, such as the negative signal in the Thermo SC-2 detection kit, cannot be used in such cases, since the absence of signal can result from low sensitivity, and not necessarily due to the presence of the mutation. However, in the absence of a better tool, the negative identification was initially used to identify the Alpha variant (Davies *et al.* 2021), and is now used by some laboratories to identify suspected BA.1 samples. The new assays described herein are straightforward, sensitive, modular and provide specific and positive identification of BA.1 and BA.2 samples. They may therefore be of immediate use for diagnostic and research laboratories, as a useful tool for detecting and differentiating between the currently circulating BA.1/BA.2 variants.




## REFERENCES

- Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee S-S. 2021. Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants. *mBio* 2021.12:e01140-21. doi.org/10.1128/mBio.01140-21.
- Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon, M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25:2000045. <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
- Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH, CMMID COVID-19 Working Group. 2021. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* 593:270–274. <https://doi.org/10.1038/s41586-021-03426-1>. [Thermo Fisher SC-2 detection kit]
- Desingu PA, Nagarajan K. Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark. *J Med Virol*. 2022 Feb 11. doi: 10.1002/jmv.27659. Epub ahead of print. PMID: 35150013.
- Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J, Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W, Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly CA. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. *Science*. 2022 Feb 8:eabn8347. doi: 10.1126/science.abn8347. Epub ahead of print. PMID: 35133177.
- Erster, O., Mendelson, E., Levy, V., Kabat, A., Mannasse, B., Asraf, H., Azar, R., Ali, Y., Shirazi, R., Bucris, E. and Bar-Ilan, D., 2021. Rapid and High-Throughput Reverse Transcriptase Quantitative PCR (RT-qPCR) Assay for Identification and Differentiation between SARS-CoV-2 Variants B. 1.1. 7 and B. 1.351. *Microbiology spectrum*, 9(2), pp.e00506-21.
- Erster, O., Mendelson, E., Kabat, A., Levy, V., Mannasse, B., Asraf, H., Azar, R., Ali, Y., Bucris, E., Bar-Ilan, D. and Mor, O., 2021. Specific Detection of Sars-Cov-2 Variants B. 1.1. 7 (Alpha) And B. 1.617. 2 (Delta) using a One-Step Quantitative Pcr Assay. medRxiv. <https://doi.org/10.1101/2021.10.11.21264831>
- Erster, O., Din, A.B., Asraf, H., Levy, V., Kabat, A., Mannasse, B., Azar, R., Shifman, O., Mandelboim, M., Fleishon, S. and Mendelson, E., 2021. Specific Detection of SARS-COV-2 B. 1.1. 529 (Omicron) Variant by four RT-qPCR Differential Assays. medRxiv. doi.org/10.1101/2021.12.07.21267293
- Lambrou AS, Shirk P, Steele MK, et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:206–211. DOI: x.doi.org/10.15585/mmwr.mm7106a4external icon.
- Pulliam, J.R., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome, M.J., Dushoff, J., Mlisana, K. and Moultrie, H., 2021. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. MedRxiv. doi.org/10.1101/2021.11.11.21266068
- Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O’Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ, McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, Sillitoe J, Kwiatkowski DP, Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM, COVID-19 Genomics UK (COG-UK) Consortium. 2021. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* 593:266–269. <https://doi.org/10.1038/s41586-021-03470-x>.
- Yu, J., Collier, A.R., Rowe, M., Mardas, F., Ventura, J., Wan, H., Miller, J., Powers, O., Chung, B., Siamatu, M. and Hachmann, N., 2022. Comparable Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants. medRxiv. doi.org/10.1101/2022.02.06.22270533


## FIGURES



**Figure 1. Specificity of selected PCR target mutations.** The target mutations selected for qPCR design were identified with respect to circulating strains by using the GISAID-based data with the NextStrain phylogenetic analysis software. The clades that contain the selected mutations are highlighted in each dendrogram. The clade annotation (BA.1, BA.2) is marked with a label and a line.



**Figure 2. Position of the BA.1/BA.2-specific reaction components.** The locations of the primers and probe of each reaction are indicated with respect to the specific mutation. The following sequences were used for the alignments: A19 (Wuhan strain) - NC\_045512, Delta sequence: Spain/CT-HUVH-04902/2021|EPI\_ISL\_2284972, BA.1 sequence: South Africa/NICD-N21672/2021|EPI\_ISL\_6704871, BA.2 sequence: Israel 8001158. Analysis was performed using the MUSCLE alignment tool embedded in the Geneious software package.



**Figure 3. Calibration of the multiplex reactions sensitivity.** *In vitro* transcribed RNA molecules containing the target sequence of each reaction were serially diluted and examined using the following reactions: E-sarbeco, N<sub>31del</sub>, S<sub>24del</sub>, S<sub>211del</sub>, Orf6<sub>D61L</sub> and RNase P. The Cq values obtained for each dilution in each reaction were plotted against the calculated concentration of target RNA copies. Target copies in concentrations down to 250 copies/reaction (Copies/RXN) were run in 8 repeats each. Target copies in a concentration below 250 Copies /RXN were run in 20 repeats. The R<sup>2</sup> value and the formula derived from the regression line of each reaction plot are shown.